MedSci参加第二届T-reg和Th17细胞研究进展及其临床应用国际会议

2010-07-20 MedSci原创 MedSci原创

2010年7月21日，第二届T-reg和Th17细胞研究进展及其临床应用国际会议于上海顺利落下帷幕。此次会议吸引了近千名海内外相关人士参加，并就相关问题进行了深入交流和讨论。本次会议的演讲者大多是国际该领域的顶尖学者，大多来自牛津、哈佛、东京知名大学及国际著名研究所，每一位学

2010年7月21日，第二届T-reg和Th17细胞研究进展及其临床应用国际会议于上海顺利落下帷幕。此次会议吸引了近千名海内外相关人士参加，并就相关问题进行了深入交流和讨论。

本次会议的演讲者大多是国际该领域的顶尖学者，大多来自牛津、哈佛、东京知名大学及国际著名研究所，每一位学者都带来了他们最新的研究成果，其中很多都未在国际期刊上发表，现场讨论热烈。本次会议还特邀国际著名期刊Nature Immunology的资深编辑Dr Laurie A. Dempsey，Immunity主编Dr Peter Lee、Journal of Clinical Investigation主编Dr Larry Turka、cell research的主编来到现场，向听众讲解各个期刊的发展历史及各位学者投稿的注意事项。

曹雪涛教授在会上讲座

各位专家热烈讨论

MedSci工作人员与Nature Immunology资深编辑Dr. Laurie A. Dempsey

MedSci工作人员与Immunity主编 Dr. Peter Lee

特别值得一提的是国内最成功的学术期刊—Cell Research，05年至08年Cell Research的影响因子分别：1.936，2.161，3.426，4.217，4.535 今年又飙升到8.151。Cell Research的创刊主编姚錱院士在创刊时就确定了国际化的办刊方向，十年呕心沥血，为期刊的发展打下了结实的基础。2006年新的主编队伍接任后（主编为裴钢院士，并从海外引进时任Cell 杂志Associate editor的李党生博士担任常务副主编），继续大力推进Cell Research国际化办刊思想和目标，锐意改革，大胆创新，为期刊快速发展带来新的机遇。近几年来，Cell Research发表了一系列高质量优秀论文并迅速引起国际反响，已逐步成为我国和国际科学家优秀科研成果的一重要传播发布平台。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2016-10-10 童小孩

好厉害

81 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2011-03-05 clmlylxy

#临床应用#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2010-07-27 ms920641618706883

#国际会议#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2010-07-22 mashirong

#研究进展#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2010-07-22 zhaojie88

#Th17#

49 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2010-07-22 ms3994565386320060

#Med#

22 0
[GetPortalCommentsPageByObjectIdResponse(id=142885, encodeId=5629142885b6, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Mon Oct 10 00:25:01 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835540, encodeId=ec401835540ce, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Mar 05 14:24:00 CST 2011, time=2011-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946717, encodeId=5f581946e1760, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Jul 27 14:24:00 CST 2010, time=2010-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380294, encodeId=81ec1380294dd, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413537, encodeId=942d141353ea7, content=<a href='/topic/show?id=9cd21e364df' target=_blank style='color:#2F92EE;'>#Th17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17364, encryptionId=9cd21e364df, topicName=Th17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605542, encodeId=e5ac160554233, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 22 02:24:00 CST 2010, time=2010-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469, encodeId=d73d14697c, content=哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=doctor, createdTime=Tue Jul 20 22:29:00 CST 2010, time=2010-07-20, status=1, ipAttribution=)]
2010-07-20 doctor

哇，真牛，可惜没机会参加这样的高端会议，我也是做免疫的呢

111 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

MedSci动态

MedSci参加第二届T-reg和Th17细胞研究进展及其临床应用国际会议

相关资讯

科室

工具

服务